MET: a promising anticancer therapeutic target.

Details

Serval ID
serval:BIB_072A0EC84335
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
MET: a promising anticancer therapeutic target.
Journal
Nature Reviews. Clinical Oncology
Author(s)
Peters S., Adjei A.A.
ISSN
1759-4782 (Electronic)
ISSN-L
1759-4774
Publication state
Published
Issued date
2012
Volume
9
Number
6
Pages
314-326
Language
english
Notes
Publication types: Journal Article ; ReviewPublication Status: epublish
Abstract
The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Thus, MET has emerged as an attractive target for cancer therapy. Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clinical trials. In general, initial results from these studies indicate only a modest benefit in unselected populations. In this Review, we discuss current challenges in developing MET inhibitors--including identification of predictive biomarkers--as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.
Keywords
Animals, Antineoplastic Agents/therapeutic use, Humans, Neoplasms/drug therapy, Neoplasms/genetics, Proto-Oncogene Proteins c-met/antagonists & inhibitors, Proto-Oncogene Proteins c-met/genetics, Signal Transduction/drug effects
Pubmed
Web of science
Create date
17/01/2013 13:14
Last modification date
20/08/2019 12:29
Usage data